Diabetic metastatic castration resistant prostate cancer patients administered mefformin during docetaxel chemotherapy have improved prostate cancer-specific and overall survival

被引：1
|
作者：
Mayer, Michelle
Klotz, Laurence
Venkateswaran, Vasundara
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1434
引用
收藏
页数：4
相关论文
共 50 条
  • [31] The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer
    Park, Jong Chul
    Pratz, Caroline F.
    Tesfaye, Anteneh
    Brodsky, Robert A.
    Antonarakis, Emmanuel S.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 32 - 38
  • [32] Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
    Hakozaki, Yuji
    Yamada, Yuta
    Kawai, Taketo
    Nakamura, Masaki
    Takeshima, Yuta
    Iwaki, Takuya
    Teshima, Taro
    Kinoshita, Yoshitaka
    Fujii, Yoichi
    Akiyama, Yoshiyuki
    Sato, Yusuke
    Yamada, Daisuke
    Suzuki, Motofumi
    Kashiwagi-Hakozaki, Mayu
    Ushiku, Tetsuo
    Kume, Haruki
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [33] IS RACE A DETERMINANT OF SURVIVAL IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER TREATED WITH DOCETAXEL?
    Ravi-Kumar, S.
    Verschraegen, C.
    Lee, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2011, 59 (01) : 117 - 117
  • [34] Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
    Yuji Hakozaki
    Yuta Yamada
    Taketo Kawai
    Masaki Nakamura
    Yuta Takeshima
    Takuya Iwaki
    Taro Teshima
    Yoshitaka Kinoshita
    Yoichi Fujii
    Yoshiyuki Akiyama
    Yusuke Sato
    Daisuke Yamada
    Motofumi Suzuki
    Mayu Kashiwagi-Hakozaki
    Tetsuo Ushiku
    Haruki Kume
    Scientific Reports, 12
  • [35] Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
    Small, E. J.
    Saad, F.
    Chowdhury, S.
    Oudard, S.
    Hadaschik, B. A.
    Graff, J. N.
    Olmos, D.
    Mainwaring, P. N.
    Lee, J. Y.
    Uemura, H.
    De Porre, P.
    Smith, A. A.
    Zhang, K.
    Lopez-Gitlitz, A.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2019, 30 (11) : 1813 - 1820
  • [36] IMPROVED SURVIVAL IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) TREATED ON CLINICAL TRIALS
    Pezaro, C.
    Omlin, A. G.
    Mukherji, D.
    Sandhu, S.
    Bianchini, D.
    Cassidy, A. Mulick
    Maier, G.
    Olmos, D.
    Attard, G.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 298 - 298
  • [37] Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC).
    Chaumard-Billotey, Natacha
    Helan, Sylvie Chabaud
    Boyle, Jane
    Favier, Bertrand
    Devaux, Yves
    Droz, Jean-Pierre
    Flechon, Aude
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC)
    Chaumard-Billotey, N.
    Aitichou, M.
    Boyle, H.
    Chabaud, S.
    Favier, B.
    Devaux, Y.
    Droz, J. P.
    Flechon, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S700 - S700
  • [39] Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
    Smaletz, O
    Scher, HI
    Small, EJ
    Verbel, DA
    McMillan, A
    Regan, K
    Kelly, WK
    Kattan, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) : 3972 - 3982
  • [40] Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
    Hoeh, Benedikt
    Wuernschimmel, Christoph
    Flammia, Rocco S.
    Horlemann, Benedikt
    Sorce, Gabriele
    Chierigo, Francesco
    Tian, Zhe
    Saad, Fred
    Graefen, Markus
    Gallucci, Michele
    Briganti, Alberto
    Terrone, Carlo
    Shariat, Shahrokh F.
    Tilki, Derya
    Kluth, Luis A.
    Mandel, Philipp
    Chun, Felix K. H.
    Karakiewicz, Pierre I.
    FRONTIERS IN ONCOLOGY, 2021, 11
12345